About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics and Mylan Agree Settlement

December 19, 2018

Click here to read more

Post navigation

Voluntary Withdrawal from OTCQX

2019 Annual General Meeting Results

Related Posts

Phosphagenics Appoints Dr Ross Murdoch as Chief Executive Officer

January 14, 2015

Reformulation of Phosphagenics Transdermal TPM/Oxymorphone Patch Complete

December 12, 2016

Avecho receives US$3M upfront payment from Sandoz AG

March 28, 2025March 28, 2025

Recent Posts

Recruitent recommences for phase III insomnia trial
August 31, 2026
Euroz Hartleys | Successful Phase 3 Interim Results
July 8, 2026
Avecho Phase III insomnia trial advances following positive interim analysis
June 24, 2026

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.